Clinical trials: Head and Neck Cancers
Head and Neck Carcinoma
Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers
This trial studies the risk of developing disorders associated with chronic opioid use post-surgery in patients with head and neck cancers.
- Trial name
- NCT03888651
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06007729
- Testing
- HS-20093
- Where
- 25 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Head and Neck Squamous Cell Carcinoma
Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma
This pilot study seeks to evaluate the feasibility of measuring the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic target molecules in Head and Neck Squamous Cell Carcinoma…
- Trial name
- NCT00620139
- Testing
- the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Head and Neck Squamous Cell Carcinoma
Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN
This study is to observe and compare the safety and tolerability of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin…
- Trial name
- NCT03117257
- Testing
- Lobaplatin, Cisplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Guiyang Medical University
Thyroid Cancer
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
This is a patient pilot study testing the hypothesis that vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR) thyroid cancer patients.
- Trial name
- NCT02456701
- Testing
- KTN3379, vemurafenib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Celldex Therapeutics
Head and Neck Cancer
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.
- Trial name
- NCT03085719
- Testing
- Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Nodule
Minimal Invasiveness of Endoscopic Thyroidectomy
The investigators had performed more than 250 cases of breast approach endoscopic thyroidectomy (BAET). The goal of this study is to evaluate whether BAET could be a minimally invasive procedure under the expert's hands.
- Trial name
- NCT00877630
- Where
- China
- Sponsor
- Second Military Medical University
Oral Cancer
Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity
Cervical nodal metastasis is the single most important prognostic factor in head and neck cancers. Appropriate management of the neck is therefore of paramount importance in the treatment of these cancers.
- Trial name
- NCT00193765
- Testing
- Elective neck dissection in early oral cancer, Therapeutic Neck Dissection
- Where
- India
- Volunteers
- 710 people
- Sponsor
- Tata Memorial Hospital
Refeeding Syndrome
The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer
The study is based on a master thesis which showed that 72% of patients with head and neck cancer admitted to a Danish hospital (Rigshospitalet, Copenhagen) developed refeeding syndrome after admission.
- Trial name
- NCT01845922
- Testing
- Low sodium diet
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Nasopharyngeal Neoplasms, Elderly
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
This prospective, multicenter, single-arm, open-label phase II clinical study aimed to investigate the efficacy and safety of intensity-modulated radiotherapy combined with lobaplatin-based concurrent chemotherapy in the…
- Conditions
- Nasopharyngeal Neoplasms, Elderly, Chemotherapy
- Trial name
- NCT06688175
- Testing
- IMRT combined with lobaplatin-based concurrent chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Nasopharyngeal Carcinoma
Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention
To study the difference in the proportion of patients with nasopharyngeal carcinoma who lost more than 10% of their body weight within 1 month after radiotherapy and chemotherapy using the mobile platform for whole-process…
- Trial name
- NCT05834712
- Testing
- mobile platform or not mobile platform
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Squamous Cell of Head and Neck
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy…
- Trial name
- NCT02585973
- Testing
- AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Neoplasm, Chemoradiation
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
In this phase II study, the investigators aim to evaluated the efficacy and toxicity of definitive concurrent chemoradiotherapy (CCRT) with docetaxel plus cisplatin (DP regimen) versus 5-fluorouracil plus cisplatin (PF regimen)…
- Trial name
- NCT02969473
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhu Yujia
Carcinoma, Squamous Cell, Head and Neck Cancer
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced…
- Trial name
- NCT02994069
- Testing
- Cisplatin, XRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Susanne Arnold
Oral Cancer
Oral Cancer Awareness in Egypt
Oral cancer is a fatal disease with high prevalence and poor survival rate. Most oral cancer cases can be detected by the patients themselves.
- Trial name
- NCT05604105
- Testing
- Questionnaire
- Volunteers
- 1,844 people, healthy volunteers welcome
- Sponsor
- Ayat Gamal-AbdelNaser
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Nasopharyngeal Carcinoma
Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage
Up to now, IMRT has largely improved the local control of locally advanced nasopharyngeal carcinoma (NPC), leaves the distant metastasis as the main treatment failure modality of patients with bulky lymph nodes (especially N3…
- Trial name
- NCT03403829
- Testing
- Gemcitabine, standard chemoradiotherapy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Fudan University
Esophageal Cancer
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer…
- Trial name
- NCT06452602
- Testing
- Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy, Induction immunochemotherapy followed by concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.